# US 2024/0199650 A1 · Pyrimidine based modulators and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0199650 A1
- Document ID: US20240199650A1
- Status: Published application
- Kind: A1
- Application number: 18/503,626
- Filed: 2023-11-07
- Published: 2024-06-20
- Earliest claimed: 2022-05-25
- Assignees: Quanta Therapeutics, Inc.
- Applicants: Quanta Therapeutics, Inc.
- Inventors: Hong LIN; Juan LUENGO; Neil JOHNSON; Audrey HOSPITAL; Jin ZENG
- Web page: https://patentgrep.com/patent/US20240199650A1

## CPC

- C07D 519/00: Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
- A61K 31/506: not condensed and containing further heterocyclic rings
- A61K 31/5377: not condensed and containing further heterocyclic rings, e.g. timolol
- A61K 31/5386: spiro-condensed or forming part of bridged ring systems
- A61K 31/55: having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K 31/551: having two nitrogen atoms, e.g. dilazep
- A61K 31/553: having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
- A61K 31/554: having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
- A61P 35/00: Antineoplastic agents
- C07D 451/02: containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
- C07D 487/04: Ortho-condensed systems
- C07D 487/08: Bridged systems
- C07D 495/00: Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Provided herein are compounds, such as compounds of Formula (I), Formula (I-A), Formula (I-B), or pharmaceutically acceptable salts of any one there, useful for modulating KRAS GD12 and/or other G12 mutants.

## Claims

### Claim 1

A compound of Formula (I):
or a pharmaceutically acceptable salt thereof wherein:
B is selected from a 7-to 15-membered heterocycle and C7-C15 carbocycle, wherein the 7-to 15-membered heterocycle and C7-Cis carbocycle are each optionally substituted with one or more substituents independently selected from halogen, —CN, —NO2, ═O, —N(R21)2, —B(OR21)2, —OR21, —SR21, —S(O)2(R21), —S(O)2N(R21)2, —NR21S(O)2R21, —C(O)N(R21)2, —C(O)NR21OR21, —N(R21)C(O)R21, —N(R21)C(O)N(R21)2, —N(R21)C(O)OR21, —C(O)R21, C(O)OR21, —OC(O)R21, —OC(O)N(R21)2, C1-6 alkyl-N(R20)2, C1-6 aminoalkyl, C1-6 alkoxy, C1-6 alkoxyalkyl, C1-6 hydroxyalkyl, C1-6 cyanoalkyl, C1-6 haloalkyl, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-C12 carbocycle and 5-to 12-membered heterocycle;
R1 is selected from hydrogen and 5-to 15-membered heterocycle, wherein the 5-to 15-membered heterocycle is optionally substituted with one or more substituents independently selected from halogen, —B(OR20)2, —OR20, —SR20, —S(O)2(R20), —S(O)2N(R20)2, —S(O)N(R20)2, —S(O)R20(═NR20), —NR20S(O)2R20, —C(O)N(R20)2, —C(═NR20)N(R20)2, —C1-6 alkyl(═NOR20), —C(O)NR20OR20, —N(R20)C(O)R20, —N(R20)C(O)N(R20)2, —N(R20)C(O)OR20, —N(R20)2, —C(O)R20, —C(O)OR20, —OC(O)R20, —OC(O)N(R20)2, —NO2, ═O, ═N(R20), ═NO(R20), —CN, —NHCN, C1-6 alkyl-N(R20)2, C1-6 aminoalkyl, C1-6 alkoxy, C1-6 hydroxyalkyl, C1-6 cyanoalkyl, C1-6 haloalkyl, C1-6 alkyl-SO2R20, C1-6 alkoxyalkyl, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-C12 carbocycle and 5-to 12-membered heterocycle, wherein the C3-C12 carbocycle and 5-to 12-membered heterocycle are each optionally substituted independently with one or more R1*;
each R1* is independently selected from halogen, —B(OR20)2, —OR20, —SR20, —S(O)2(R20), —S(O)2N(R20)2, —S(O)N(R20)2, —S(O)R20(═NR20), —NR20S(O)2R20, —C(O)N(R20)2, —C(O)NR20OR20, —N(R20)C(O)R20, —N(R20)C(O)N(R20)2, —N(R20)C(O)OR20, —N(R20)2, —C(O)R20, —C(O)OR20, —OC(O)R20, —OC(O)N(R20)2, —NO2, ═O, ═N(R20), ═NO(R20), —CN, —NHCN, C1-6 alkyl-N(R20)2, C1-6 aminoalkyl, C1-6 alkoxy, C1-6 hydroxyalkyl, C1-6 cyanoalkyl, C1-6 haloalkyl, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, and C3-C12 carbocycle;
Y is —O—;
R2 is selected from heterocycle, -L-heterocycle, -L-N(R23)2, and -L-aryl, wherein the heterocycle, and the heterocycle portion of -L-heterocycle are each optionally substituted with one or more R6, and wherein the aryl of the -L-aryl is optionally substituted with one or more R7;
R3 is selected from hydrogen, halogen, —CN, —NO2, —N(R20)2, —OR20, —SR20, —S(O)2(R20), —S(O)2N(R20)2, —S(O)N(R20)2, —S(O)R20(═NR20), —NR20S(O)2R20, —C(O)N(R20)2, —N(R20)C(O)R20, —N(R20)C(O)N(R20)2, —N(R20)C(O)OR20, —C(O)R20, —C(O)OR20, —OC(O)R20, —OC(O)N(R20)2, C1-6 alkyl-N(R20)2, C1-6 aminoalkyl, C1-6 alkoxy, C1-6 alkoxyalkyl, C1-6 hydroxyalkyl, C1-6 cyanoalkyl, C1-6 haloalkyl, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-C12 carbocycle and 5-to 12-membered heterocycle;
each R4 is independently selected from halogen, —NO2, ═O, ═S, —CN, C1-6 alkyl, C2-6 alkynyl, C1-6 alkyl-N(R20)2, C1-6 aminoalkyl, C1-6 alkoxy, C1-6 cyanoalkyl, C1-6 hydroxyalkyl, and C1-6 haloalkyl;
n is selected from 0, 1, 2, 3, and 4;
each R5 is independently selected from hydrogen and C1-C6 alkyl;
each R6 is independently selected from halogen, hydroxy, C1-C3 hydroxyalkyl, C1-C3 alkyl, oxo, C1-C3 haloalkyl, C1-C3 alkoxy, cyano, ═CH2, ═NO—C1-C3 alkyl, C1-C3 aminoalkyl, —N(R5)S(O)2(R5), -Q-phenyl, -Q-phenylSO2F, —NHC(O)phenyl, —NHC(O)phenylSO2F, C1-C3 alkyl substituted pyrazolyl, —C1-C3 alkyl-N(R5)2, —C(O)N(R5)2, —C1-C3 alkyl-N(R5)2, —C(O)N(R5)2, tert-butyldimethylsilyloxyCH2—, —N(R5)2, (C1-C3 alkoxy)C1-C3 alkyl-, (C1-C3 alkyl)C(═O), oxo, (C1-C3 haloalkyl)C(═O)—, —SO2F, (C1-C3 alkoxy)C1-C3 alkoxy, —CH2OC(O)N(R5)2, —CH2NHC(O)OC1-C6 alkyl, —CH2NHC(O)N(R5)2, —CH2NHC(O)C1-C6 alkyl, —CH2(pyrazolyl), —CH2NHSO2C1-C6 alkyl, —CH2OC(O)heterocycle, —OC(O)N(R5)2, —OC(O)NH(C1-C3 alkyl)O(C1-C3 alkyl), —OC(O)NH(C1-C3 alkyl)O(C1-C3 alkyl)phenyl(C1-C3 alkyl)N(CH3)2, —OC(O)NH(C1-C3 alkyl)O(C1-C3 alkyl)phenyl, —OC(O)heterocycle, —O—C1-C3 alkyl, —S(O)2(R20), —S(O)2N(R20)2, —S(O)N(R20)2, —S(O)R20(═NR20), —NR20S(O)2R20, and —CH2 heterocycle, wherein the phenyl of —NHC(O)phenyl and —OC(O)NH(C1-C3 alkyl)(C1-C3 alkyl)phenyl are optionally substituted with one or more substituents selected from —C(O)H and OH, and wherein the alkyl of —O—C1-C3 alkyl is optionally substituted with substituents selected from heterocycle, oxo and hydroxy; and wherein the heterocycle of —CH2 heterocyclyl is optionally substituted with oxo;
each Q is selected from a bond, S, and O;
each R7 is independently selected from halogen, hydroxy, HC(═O)—, C1-C4 alkyl, C1-C4 alkoxy, C1-C4 haloalkyl, C1-C4 hydroxyalkyl, —C1-C3 alkyl-N(R5)2, —C(O)N(R5)2, and —N(R5)2;
each L is independently selected from a C1-C4 alkylene optionally substituted with one or more substituents independently selected from halogen, hydroxy, C1-6 alkoxy, C1-C4 hydroxyalkyl, C1-C4 alkyl, C3-C6 carbocycle, and 3-to 8-membered heterocycle, wherein the C3-C6 carbocycle and 3-to 8-membered heterocycle are each optionally substituted with one or more substituents independently selected from halogen, —OH, —NO2, ═O, ═S, —CN, C1-6 alkyl-N(R20)2, C1-6 aminoalkyl, C1-6 alkoxy, C1-6 hydroxyalkyl, C1-6 haloalkyl; and wherein optionally two substituents on the same carbon atom of L come together to form a C3-C6 carbocycle or 3-to 8-membered heterocycle, wherein the C3-C6 carbocycle and 3-to 8-membered heterocycle are each optionally substituted with one or more substituents independently selected from halogen, —OH, —NO2, ═O, ═S, —CN, C1-6 alkyl-N(R20)2, C1-6 aminoalkyl, C1-6 alkoxy, C1-6 hydroxyalkyl, and C1-6 haloalkyl;
each R20 is independently selected from hydrogen; and C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-12 carbocycle, and 3-to 12-membered heterocycle, each of which is optionally substituted with one or more substituents independently selected from halogen, —OH, —CN, —NO2, —NH2, —N(C1-6 alkyl)2, C1-10 alkyl, —C1-10 haloalkyl, —O—C1-10 alkyl, oxo, C3-12 carbocycle, and 3-to 12-membered heterocycle;
each R21 is independently selected from hydrogen; and C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-12 carbocycle, and 3-to 12-membered heterocycle, each of which is optionally substituted with one or more substituents independently selected from halogen, —OH, —CN, —NO2, —NH2, —N(C1-6 alkyl)2, C1-10 alkyl, —C1-10 haloalkyl, —O—C1-10 alkyl, oxo, C3-12 carbocycle, and 3-to 12-membered heterocycle; and
each R23 is independently selected from hydrogen; and C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-12 carbocycle, and 3-to 12-membered heterocycle, each of which is optionally substituted with one or more substituents independently selected from halogen, —OH, —CN, —NO2, —NH2, —N(C1-6 alkyl)2, C1-10 alkyl, —C1-10 haloalkyl, —O—C1-10 alkyl, oxo, C3-12 carbocycle, and 3-to 12-membered heterocycle.

### Claim 2 (depends on 1)

The compound or salt of claim 1, wherein B is selected from an optionally substituted 7-to 11-membered fused heterocycle, wherein B has at least one sulfur atom.

### Claim 3 (depends on 2)

The compound or salt of claim 2, wherein B is selected from
each of which is optionally substituted with one or more optional substituents independently selected at each occurrence from halogen, C1-C3 alkyl, —NH2, and —CN.

### Claim 4 (depends on 1)

The compound or salt of claim 1, wherein B is selected from

### Claim 5 (depends on 1)

The compound or salt of claim 1, wherein R3 is selected from hydrogen, halogen, —CN, —NO2, —S(O)2(R20), —S(O)2N(R20)2, —S(O)N(R20)2, —S(O)R20(═NR20), —NR20S(O)2R20, —C(O)N(R20)2, —N(R20)C(O)R20, —N(R20)C(O)N(R20)2, —N(R20)C(O)OR20, —C(O)R20, —C(O)OR20, —C1-6 alkyl-N(R20)2, C1-6 aminoalkyl, C1-6 alkoxy, C1-6 alkoxyalkyl, C1-6 hydroxyalkyl, C1-6 cyanoalkyl, C1-6 haloalkyl, C1-6 alkyl, C2-6 alkenyl, and C2-6 alkynyl.

### Claim 6 (depends on 5)

The compound or salt of claim 5, wherein R3 is selected from hydrogen, fluorine, and —CN.

### Claim 7 (depends on 1)

The compound or salt of claim 1, wherein each L is independently selected from an optionally substituted C1-C4 alkylene; and wherein optionally two substituents on the same carbon atom of L come together to form a C3-C6 carbocycle or 3-to 8-membered heterocycle, wherein the C3-C6 carbocycle and 3-to 8-membered heterocycle are each optionally substituted with one or more substituents selected from halogen, —OH, —NO2, ═O, ═S, —CN, C1-6 aminoalkyl, C1-6alkoxy, C1-6 hydroxyalkyl, and C1-6haloalkyl.

### Claim 8 (depends on 1)

The compound or salt of claim 1, wherein Y—R2 is selected from

### Claim 9 (depends on 1)

The compound or salt of claim 1, wherein Y—R2 is selected from

### Claim 10 (depends on 1)

The compound or salt of claim 1, wherein R1 is selected from 8-to 10-membered heterocycle, wherein the 8-to 10-membered heterocycle is optionally substituted with one or more substituents independently selected from halogen, —OR20, —S(O)2(R20), —C(O)N(R20)2, —C1-6 alkyl(═NOR20), —C(O)R20, ═O, —CN, —NHCN, C1-6 alkyl-N(R20)2, C1-6 aminoalkyl, C1-6 alkoxy, C1-6 hydroxyalkyl, C1-6 cyanoalkyl, C1-6 haloalkyl, C1-6 alkyl-SO2R20, C1-6 alkoxyalkyl, C1-6 alkyl, C2-6 alkynyl, and 5-to 12-membered heterocycle, wherein the 5-to 12-membered heterocycle are each optionally substituted independently with one or more R1*;
and wherein each R1* is independently selected from halogen, —OR20, —N(R20)2, —NO2, ═O, ═N(R20), ═NO(R20), —CN, —NHCN, C1-6 alkyl-N(R20)2, C1-6 aminoalkyl, C1-6 alkoxy, C1-6 hydroxyalkyl, C1-6 cyanoalkyl, C1-6 haloalkyl, and C1-6 alkyl.

### Claim 11 (depends on 10)

The compound or salt of claim 10, wherein R1 is
optionally substituted with one or more substituents independently selected from halogen, —S(O)2(R20), —C(O)N(R20)2, —C1-6 alkyl(═NOR20), —C(O)R20, ═O, and 5-to 9-membered heterocycle, wherein the 5-to-membered heterocycle are each optionally substituted independently with one or more R1*.

### Claim 12 (depends on 1)

The compound or salt of claim 1, wherein R1 is selected from

### Claim 13 (depends on 1)

The compound or salt of claim 1, wherein R1 is selected from

### Claim 14 (depends on 1)

The compound or salt of claim 1, wherein R1 is

### Claim 15 (depends on 1)

The compound or salt of claim 1, wherein R1 is

### Claim 16 (depends on 1)

The compound or salt of claim 1, wherein R1 is

### Claim 17 (depends on 1)

The compound or salt of claim 1, wherein the compound is selected from
or a pharmaceutically salt of any one thereof.

### Claim 18 (depends on 1)

A pharmaceutical composition comprising the compound or salt of claim 1, or a compound selected from
or a pharmaceutically salt of any one thereof, and
a pharmaceutically acceptable excipient.

### Claim 19 (depends on 18)

A method of treating a disease or disorder, comprising administering to a subject in need thereof, the pharmaceutical composition of claim 18, or a compound or salt selected from
or a pharmaceutically acceptable salt of any one thereof.

### Claim 20 (depends on 19)

The method of claim 19, wherein the disease or disorder is a KRas G12D or other G12 mutants-associated cancer.

### Claim 21 (depends on 19)

The method of claim 19, wherein the disease or disorder is a cancer selected from:
Cardiac: sarcoma (angiosarcoma, fibrosarcoma, rhabdomyosarcoma, liposarcoma), myxoma, rhabdomyoma, fibroma, lipoma and teratoma;
Lung: bronchogenic carcinoma (squamous cell, undifferentiated small cell, undifferentiated large cell, adenocarcinoma), alveolar (bronchiolar) carcinoma, bronchial adenoma, sarcoma, lymphoma, chondromatous hamartoma, mesothelioma;
Gastrointestinal: esophagus (squamous cell carcinoma, adenocarcinoma, leiomyosarcoma, lymphoma), stomach (carcinoma, lymphoma, leiomyosarcoma), pancreas (ductal adenocarcinoma, insulinoma, glucagonoma, gastrinoma, carcinoid tumors, vipoma), small bowel (adenocarcinoma, lymphoma, carcinoid tumors, Kaposi's sarcoma, leiomyoma, hemangioma, lipoma, neurofibroma, fibroma), large bowel (adenocarcinoma, tubular adenoma, villous adenoma, hamartoma, leiomyoma);
Genitourinary tract: kidney (adenocarcinoma, Wilm's tumor (nephroblastoma), lymphoma, leukemia), bladder and urethra (squamous cell carcinoma, transitional cell carcinoma, adenocarcinoma), prostate (adenocarcinoma, sarcoma), testis (seminoma, teratoma, embryonal carcinoma, teratocarcinoma, choriocarcinoma, sarcoma, interstitial cell carcinoma, fibroma, fibroadenoma, adenomatoid tumors, lipoma);
Liver: hepatoma (hepatocellular carcinoma), cholangiocarcinoma, hepatoblastoma, angiosarcoma, hepatocellular adenoma, hemangioma;
Biliary tract: gall bladder carcinoma, ampullary carcinoma, cholangiocarcinoma;
Bone: osteogenic sarcoma (osteosarcoma), fibrosarcoma, malignant fibrous histiocytoma, chondrosarcoma, Ewing's sarcoma, malignant lymphoma (reticulum cell sarcoma), multiple myeloma, malignant giant cell tumor chordoma, osteochronfroma (osteocartilaginous exostoses), benign chondroma, chondroblastoma, chondromyxofibroma, osteoid osteoma and giant cell tumors;
Nervous system: skull (osteoma, hemangioma, granuloma, xanthoma, osteitis deformans), meninges (meningioma, meningiosarcoma, gliomatosis), brain (astrocytoma, medulloblastoma, glioma, ependymoma, germinoma (pinealoma), glioblastoma multiform, oligodendroglioma, schwannoma, retinoblastoma, congenital tumors), spinal cord neurofibroma, meningioma, glioma, sarcoma);
Gynecological: uterus (endometrial carcinoma), cervix (cervical carcinoma, pre-tumor cervical dysplasia), ovaries (ovarian carcinoma (serous cystadenocarcinoma, mucinous cystadenocarcinoma, unclassified carcinoma), granulosa-thecal cell tumors, Sertoli-Leydig cell tumors, dysgerminoma, malignant teratoma), vulva (squamous cell carcinoma, intraepithelial carcinoma, adenocarcinoma, fibrosarcoma, melanoma), vagina (clear cell carcinoma, squamous cell carcinoma, botryoid sarcoma (embryonal rhabdomyosarcoma), fallopian tubes (carcinoma);
Hematologic: blood (myeloid leukemia (acute and chronic), acute lymphoblastic leukemia, chronic lymphocytic leukemia, myeloproliferative diseases, multiple myeloma, myelodysplastic syndrome), Hodgkin's disease, non-Hodgkin's lymphoma (malignant lymphoma);
Skin: malignant melanoma, basal cell carcinoma, squamous cell carcinoma, Kaposi's sarcoma, moles dysplastic nevi, lipoma, angioma, dermatofibroma, keloids, psoriasis; and
Adrenal glands: neuroblastoma.

### Claim 22 (depends on 19)

The method of claim 19, wherein the disease or disorder is a cancer, wherein the cancer is non-small cell lung cancer, small cell lung cancer, colorectal cancer, rectal cancer or pancreatic cancer; or wherein the cancer is a tumor cancer.
